Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tiotropium bromide.

David A Lipson1

  • 1Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA. dlipson@mail.med.upenn.edu

International Journal of Chronic Obstructive Pulmonary Disease
|December 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial biogeography of microbes in soils vs. aquatic ecosystems in U.S.'s major natural biomes.

Frontiers in microbiology·2026
Same author

Effects of seasonality and treatment on COPD clinical outcomes: IMPACT <i>post hoc</i> analysis.

ERJ open research·2025
Same author

The Effect of Patient Sex on Treatment Outcomes in COPD: A Post Hoc Analysis of the IMPACT Trial.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2024
Same author

ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD.

The European respiratory journal·2024
Same author

Thermokarst landscape exhibits large nitrous oxide emissions in Alaska's coastal polygonal tundra.

Communications earth & environment·2024
Same author

Any Decrease in Lung Function is Associated With Worse Clinical Outcomes: Post Hoc Analysis of the IMPACT Interventional Trial.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2023
Same journal

SPG7-Mediated Regulation of mPTP and Mitochondrial Flickering in COPD: A Bioinformatics-Based Prediction of Mechanistic Framework.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Prognostic Value of Chest CT-Derived Pectoralis Muscle Metrics for In-Hospital Mortality and Invasive Mechanical Ventilation in AECOPD.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Clinical Disease Burden in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation in Japan: A Retrospective Database Analysis (EUROS Study).

International journal of chronic obstructive pulmonary disease·2026
Same journal

Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study [Letter].

International journal of chronic obstructive pulmonary disease·2026
Same journal

Real-Life Effectiveness of Aclidinium/Formoterol on COPD Control: The REDACT Observational Study.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Effective-Component Compatibility of Bufei Yishen Formula Alleviates Alveolar Epithelial Barrier Damage in COPD Through Inhibition of p38 MAPK Phosphorylation.

International journal of chronic obstructive pulmonary disease·2026
See all related articles

Bronchodilators improve symptoms and quality of life for COPD patients but do not alter disease progression. Tiotropium bromide offers improved symptom management, but comprehensive care is essential.

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Bronchodilators are foundational in COPD treatment, improving dyspnea and exercise performance.
  • Current bronchodilators do not impact COPD progression or survival rates.
  • Tiotropium bromide, a novel long-acting anticholinergic, shows promise for symptom management.

Purpose of the Study:

  • To review anticholinergic pharmacologic therapy for COPD.
  • To focus on tiotropium bromide's role in COPD symptom management.
  • To discuss COPD treatment strategies tailored to disease stage.

Main Methods:

  • Literature review of anticholinergic pharmacologic therapy in COPD.
  • Focus on tiotropium bromide efficacy and application.
  • Analysis of treatment strategies based on COPD disease severity.

Related Experiment Videos

Main Results:

  • Bronchodilators significantly improve COPD symptoms like dyspnea and enhance quality of life.
  • Tiotropium bromide offers a new option for managing COPD symptoms.
  • No evidence suggests bronchodilators alter the rate of FEV1 decline or improve survival.

Conclusions:

  • Anticholinergic therapy, particularly tiotropium bromide, can improve symptom control in COPD.
  • While bronchodilators alleviate symptoms, they do not halt COPD progression.
  • Optimal COPD care necessitates a multimodality approach beyond pharmacologic therapy.